A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period

NCT02587195 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Teriflunomide

Sponsor

Centre Hospitalier Universitaire de Nice